The new company, whose name was not disclosed, will provide preclinical and clinical immune monitoring and biomarker services to biopharma companies.
Financial analysts seemed convinced of the long-term advantages of the deal but noted that investors may remain skeptical in the near term.
NEC said the deal will bolster its cancer immunotherapy development programs, which are focused on ovarian cancer and head and neck cancer.
The company's total revenues were $114.1 million compared with $95.6 million in the same quarter last year, beating analysts' expectations.
Exact said it will pay $72 per share for Genomic Health for a total transaction price of $2.8 billion in cash and stock.
EdiGene has developed a diploid library of 2,800 single clonal knockout cell lines, targeting 2,600 genes in commonly used human cancer cell lines.
Invitae sees Jungla's AI platform as complementary to its own variant classification and interpretation methods.
The first application of the technology will be for noninvasive prenatal screening followed by cancer liquid biopsy testing.
Vermont-based BioTek is a privately held company that manufactures and sells life science instruments, including cell imaging systems.
As expected, the UK's Competition and Markets Authority is referring the proposed Illumina acquisition of PacBio for an in-depth Phase 2 investigation.
New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.
A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.
Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.
In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.